Yet, patients treated with tezepelumab have a reduced airway hyperresponsiveness and this effect may be due to inhibition of MCs, as TSLP mediates the activation of MCs located in ASMs and airway hyperresponsiveness is generally not improved by biologics that inhibit specifically eosinophilic inflammation [141]. Here, TSLP is linked to airway hyperresponsiveness.